Kathleen Victoria Fitch, M.S.N.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 73 | 2022 | 15538 | 3.130 |
Why?
|
Plaque, Atherosclerotic | 12 | 2023 | 1365 | 1.290 |
Why?
|
HIV | 10 | 2023 | 1489 | 1.070 |
Why?
|
Coronary Artery Disease | 16 | 2023 | 6213 | 0.990 |
Why?
|
Cardiovascular Diseases | 17 | 2022 | 14075 | 0.960 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2022 | 3097 | 0.850 |
Why?
|
Life Style | 5 | 2019 | 3636 | 0.780 |
Why?
|
Atherosclerosis | 8 | 2023 | 3228 | 0.720 |
Why?
|
Amino Acids | 3 | 2020 | 1752 | 0.700 |
Why?
|
Diet Therapy | 1 | 2019 | 159 | 0.700 |
Why?
|
Quinolines | 6 | 2020 | 737 | 0.630 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 5 | 2021 | 138 | 0.620 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1513 | 0.550 |
Why?
|
Renin-Angiotensin System | 6 | 2022 | 754 | 0.530 |
Why?
|
Monocytes | 4 | 2018 | 2660 | 0.530 |
Why?
|
Fibrosis | 2 | 2018 | 1947 | 0.480 |
Why?
|
Bone Diseases | 2 | 2019 | 423 | 0.470 |
Why?
|
Adiposity | 7 | 2021 | 1734 | 0.450 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 5 | 2018 | 312 | 0.450 |
Why?
|
Tunica Media | 2 | 2011 | 122 | 0.430 |
Why?
|
Inflammation | 14 | 2023 | 10019 | 0.430 |
Why?
|
Nutrition Disorders | 1 | 2011 | 214 | 0.410 |
Why?
|
Dyslipidemias | 3 | 2019 | 843 | 0.410 |
Why?
|
Asymptomatic Diseases | 5 | 2018 | 577 | 0.410 |
Why?
|
Subcutaneous Fat | 5 | 2019 | 384 | 0.390 |
Why?
|
Patient Selection | 2 | 2020 | 4306 | 0.380 |
Why?
|
Tunica Intima | 2 | 2011 | 498 | 0.370 |
Why?
|
Intra-Abdominal Fat | 4 | 2019 | 578 | 0.360 |
Why?
|
Metformin | 2 | 2014 | 800 | 0.360 |
Why?
|
Middle Aged | 65 | 2022 | 213752 | 0.350 |
Why?
|
Arteritis | 2 | 2022 | 133 | 0.350 |
Why?
|
Aging | 3 | 2020 | 8358 | 0.340 |
Why?
|
Fingers | 1 | 2011 | 518 | 0.330 |
Why?
|
Diet | 4 | 2022 | 7392 | 0.330 |
Why?
|
Neck | 2 | 2016 | 698 | 0.320 |
Why?
|
Ribonuclease III | 2 | 2021 | 275 | 0.310 |
Why?
|
Adipose Tissue, Brown | 4 | 2019 | 810 | 0.310 |
Why?
|
Carotid Arteries | 1 | 2011 | 977 | 0.300 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 238 | 0.300 |
Why?
|
Adipose Tissue | 5 | 2021 | 3234 | 0.300 |
Why?
|
DEAD-box RNA Helicases | 2 | 2021 | 357 | 0.300 |
Why?
|
Calcinosis | 2 | 2012 | 1435 | 0.290 |
Why?
|
Body Composition | 12 | 2019 | 2393 | 0.280 |
Why?
|
Anti-HIV Agents | 9 | 2020 | 4062 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 9488 | 0.270 |
Why?
|
Male | 63 | 2023 | 349524 | 0.270 |
Why?
|
Adult | 46 | 2022 | 211041 | 0.260 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1110 | 0.260 |
Why?
|
Receptors, Cell Surface | 5 | 2018 | 2913 | 0.250 |
Why?
|
Anti-Retroviral Agents | 4 | 2020 | 1572 | 0.250 |
Why?
|
Viral Load | 8 | 2022 | 3231 | 0.250 |
Why?
|
Female | 62 | 2023 | 375205 | 0.250 |
Why?
|
Humans | 83 | 2023 | 708843 | 0.240 |
Why?
|
Nutritional Status | 1 | 2011 | 1532 | 0.240 |
Why?
|
Exercise | 1 | 2019 | 5251 | 0.240 |
Why?
|
Insulin Resistance | 6 | 2021 | 3866 | 0.240 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 794 | 0.230 |
Why?
|
Antigens, CD | 5 | 2018 | 4169 | 0.230 |
Why?
|
Risk Factors | 19 | 2023 | 69553 | 0.230 |
Why?
|
Sex Factors | 7 | 2019 | 10566 | 0.230 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2019 | 95 | 0.200 |
Why?
|
Hepacivirus | 1 | 2018 | 1309 | 0.200 |
Why?
|
Lipoproteins, LDL | 3 | 2022 | 660 | 0.190 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 126 | 0.190 |
Why?
|
Hyperinsulinism | 2 | 2017 | 405 | 0.190 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 2734 | 0.190 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 37 | 0.180 |
Why?
|
Prevalence | 7 | 2022 | 14712 | 0.180 |
Why?
|
Sweetening Agents | 1 | 2021 | 289 | 0.180 |
Why?
|
Absorptiometry, Photon | 2 | 2019 | 1692 | 0.180 |
Why?
|
Methylamines | 2 | 2016 | 108 | 0.180 |
Why?
|
Proteomics | 3 | 2022 | 3244 | 0.180 |
Why?
|
Serum | 2 | 2019 | 219 | 0.170 |
Why?
|
Comorbidity | 5 | 2020 | 10339 | 0.170 |
Why?
|
Young Adult | 15 | 2021 | 55940 | 0.170 |
Why?
|
Research Subjects | 1 | 2020 | 247 | 0.170 |
Why?
|
Heart Diseases | 1 | 2011 | 2759 | 0.170 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4658 | 0.170 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 382 | 0.170 |
Why?
|
Blood Proteins | 2 | 2020 | 1144 | 0.170 |
Why?
|
Hepatitis C | 1 | 2018 | 1493 | 0.170 |
Why?
|
Tomography, X-Ray | 1 | 2016 | 60 | 0.160 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 140 | 0.160 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 23020 | 0.150 |
Why?
|
Food Supply | 1 | 2022 | 457 | 0.150 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2543 | 0.150 |
Why?
|
Adolescent | 18 | 2021 | 84718 | 0.150 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2022 | 611 | 0.140 |
Why?
|
Body Mass Index | 8 | 2021 | 12366 | 0.140 |
Why?
|
Angiography | 3 | 2016 | 1675 | 0.140 |
Why?
|
Muscle Cells | 1 | 2016 | 200 | 0.140 |
Why?
|
Smoking | 1 | 2013 | 8612 | 0.140 |
Why?
|
Sodium | 2 | 2022 | 1637 | 0.140 |
Why?
|
Gender Identity | 1 | 2020 | 554 | 0.140 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2090 | 0.140 |
Why?
|
Antiviral Agents | 1 | 2018 | 2768 | 0.140 |
Why?
|
Pravastatin | 1 | 2017 | 390 | 0.140 |
Why?
|
Triglycerides | 3 | 2020 | 2564 | 0.130 |
Why?
|
Macrophage Activation | 1 | 2018 | 596 | 0.130 |
Why?
|
Nutrition Policy | 1 | 2019 | 471 | 0.130 |
Why?
|
Diet Surveys | 1 | 2019 | 1157 | 0.130 |
Why?
|
Interleukin-10 | 1 | 2020 | 1213 | 0.130 |
Why?
|
Aged | 19 | 2022 | 161488 | 0.130 |
Why?
|
HIV-1 | 5 | 2020 | 6757 | 0.120 |
Why?
|
Blood Coagulation Disorders | 1 | 2016 | 341 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2019 | 869 | 0.120 |
Why?
|
Cholesterol, LDL | 4 | 2019 | 2351 | 0.120 |
Why?
|
Adipose Tissue, White | 1 | 2016 | 354 | 0.120 |
Why?
|
Pericardium | 1 | 2018 | 665 | 0.120 |
Why?
|
Cholesterol, HDL | 2 | 2013 | 1817 | 0.120 |
Why?
|
International Cooperation | 1 | 2020 | 1434 | 0.120 |
Why?
|
Regression Analysis | 3 | 2013 | 6451 | 0.120 |
Why?
|
Minority Groups | 1 | 2020 | 1077 | 0.120 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 312 | 0.110 |
Why?
|
Menopause | 1 | 2020 | 1518 | 0.110 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 128 | 0.110 |
Why?
|
Boston | 2 | 2019 | 9402 | 0.110 |
Why?
|
Anticholesteremic Agents | 2 | 2017 | 964 | 0.110 |
Why?
|
Cardiovascular System | 1 | 2018 | 767 | 0.110 |
Why?
|
Sex Characteristics | 2 | 2023 | 2510 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 20308 | 0.100 |
Why?
|
Fenofibrate | 1 | 2011 | 92 | 0.100 |
Why?
|
Niacin | 1 | 2011 | 113 | 0.100 |
Why?
|
Fibronectins | 1 | 2014 | 734 | 0.100 |
Why?
|
Prospective Studies | 8 | 2022 | 50597 | 0.100 |
Why?
|
Iodide Peroxidase | 1 | 2012 | 278 | 0.100 |
Why?
|
Case-Control Studies | 7 | 2020 | 21194 | 0.100 |
Why?
|
Intestinal Diseases | 1 | 2015 | 507 | 0.100 |
Why?
|
Proteome | 1 | 2020 | 1767 | 0.100 |
Why?
|
Osteoporosis | 1 | 2019 | 1556 | 0.100 |
Why?
|
Pulsatile Flow | 1 | 2011 | 334 | 0.100 |
Why?
|
Hyperemia | 1 | 2011 | 226 | 0.100 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 2032 | 0.100 |
Why?
|
Vaccination | 1 | 2022 | 2864 | 0.100 |
Why?
|
Double-Blind Method | 6 | 2019 | 11877 | 0.090 |
Why?
|
Manometry | 1 | 2011 | 419 | 0.090 |
Why?
|
Calorimetry, Indirect | 1 | 2009 | 178 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6562 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1356 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1819 | 0.090 |
Why?
|
Coronary Angiography | 3 | 2019 | 4383 | 0.090 |
Why?
|
Lipodystrophy | 2 | 2006 | 146 | 0.090 |
Why?
|
Fibroblast Growth Factors | 1 | 2014 | 878 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2016 | 2244 | 0.090 |
Why?
|
Blood Pressure | 4 | 2018 | 8528 | 0.080 |
Why?
|
African Americans | 2 | 2022 | 5118 | 0.080 |
Why?
|
Blood Glucose | 3 | 2021 | 6255 | 0.080 |
Why?
|
Stavudine | 1 | 2007 | 91 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2017 | 1578 | 0.080 |
Why?
|
Patient Participation | 1 | 2017 | 1447 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 1938 | 0.080 |
Why?
|
Extremities | 1 | 2012 | 875 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2012 | 1988 | 0.080 |
Why?
|
Coronary Vessels | 2 | 2016 | 2964 | 0.080 |
Why?
|
Hypertension | 2 | 2019 | 8161 | 0.080 |
Why?
|
Adipogenesis | 2 | 2021 | 349 | 0.070 |
Why?
|
Hyperlipidemias | 1 | 2011 | 796 | 0.070 |
Why?
|
Mitochondria, Muscle | 1 | 2007 | 174 | 0.070 |
Why?
|
Treatment Outcome | 8 | 2018 | 61932 | 0.070 |
Why?
|
Immunity | 1 | 2011 | 957 | 0.070 |
Why?
|
Liver | 2 | 2021 | 7622 | 0.070 |
Why?
|
MicroRNAs | 1 | 2021 | 3655 | 0.070 |
Why?
|
Cholesterol | 1 | 2014 | 2866 | 0.070 |
Why?
|
Energy Metabolism | 3 | 2016 | 2968 | 0.070 |
Why?
|
Vitamin D | 1 | 2019 | 3138 | 0.070 |
Why?
|
Aldosterone | 2 | 2022 | 799 | 0.070 |
Why?
|
Back | 2 | 2016 | 69 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3690 | 0.070 |
Why?
|
Health Promotion | 1 | 2017 | 2172 | 0.070 |
Why?
|
Diet, Sodium-Restricted | 2 | 2016 | 274 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3562 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4315 | 0.060 |
Why?
|
Chemokine CCL2 | 2 | 2017 | 658 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 13314 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2011 | 901 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18712 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2408 | 0.060 |
Why?
|
Glucose Clamp Technique | 2 | 2018 | 259 | 0.060 |
Why?
|
Body Size | 1 | 2006 | 466 | 0.060 |
Why?
|
Waist Circumference | 2 | 2019 | 895 | 0.060 |
Why?
|
Eating | 1 | 2009 | 1443 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2006 | 830 | 0.060 |
Why?
|
Nucleosides | 1 | 2022 | 137 | 0.060 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 328 | 0.060 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2021 | 24 | 0.060 |
Why?
|
Up-Regulation | 1 | 2012 | 4353 | 0.060 |
Why?
|
Latent TGF-beta Binding Proteins | 1 | 2021 | 43 | 0.060 |
Why?
|
Lipids | 2 | 2018 | 3246 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5348 | 0.050 |
Why?
|
Treatment Failure | 1 | 2018 | 2680 | 0.050 |
Why?
|
Primary Prevention | 2 | 2019 | 1134 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 23284 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5908 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 12031 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 114 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.050 |
Why?
|
Receptors, Purinergic P2X5 | 1 | 2019 | 7 | 0.050 |
Why?
|
Obesity, Abdominal | 2 | 2015 | 335 | 0.050 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2019 | 42 | 0.050 |
Why?
|
Integrases | 1 | 2022 | 553 | 0.050 |
Why?
|
Ultrasonography | 2 | 2011 | 5918 | 0.050 |
Why?
|
Reproduction | 2 | 2020 | 639 | 0.050 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1928 | 0.050 |
Why?
|
Interleukin-18 | 1 | 2021 | 248 | 0.050 |
Why?
|
Massachusetts | 1 | 2013 | 8712 | 0.050 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6170 | 0.050 |
Why?
|
Dietary Fats | 1 | 2007 | 2042 | 0.040 |
Why?
|
Glucose | 2 | 2012 | 4261 | 0.040 |
Why?
|
Phenotype | 1 | 2016 | 16306 | 0.040 |
Why?
|
North America | 1 | 2022 | 1174 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4317 | 0.040 |
Why?
|
HIV Integrase Inhibitors | 1 | 2019 | 119 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2021 | 600 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12447 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 152 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 39292 | 0.040 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 264 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2019 | 435 | 0.040 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2018 | 161 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2022 | 777 | 0.040 |
Why?
|
Symporters | 1 | 2019 | 366 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 460 | 0.040 |
Why?
|
Hormones | 2 | 2014 | 855 | 0.040 |
Why?
|
Galectin 3 | 1 | 2018 | 217 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1896 | 0.040 |
Why?
|
Galectins | 1 | 2018 | 246 | 0.040 |
Why?
|
History, 21st Century | 1 | 2022 | 1569 | 0.030 |
Why?
|
Malnutrition | 1 | 2022 | 620 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1421 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 585 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2020 | 3700 | 0.030 |
Why?
|
Gene Silencing | 1 | 2021 | 1626 | 0.030 |
Why?
|
Body Fat Distribution | 1 | 2016 | 242 | 0.030 |
Why?
|
Adipocytes | 1 | 2021 | 1181 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 8014 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 1156 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 3093 | 0.030 |
Why?
|
Choline | 1 | 2015 | 471 | 0.030 |
Why?
|
Income | 1 | 2021 | 1775 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 12863 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1633 | 0.030 |
Why?
|
Angiotensin II | 1 | 2015 | 921 | 0.030 |
Why?
|
Community Health Services | 1 | 2017 | 661 | 0.030 |
Why?
|
Self Report | 1 | 2022 | 3397 | 0.030 |
Why?
|
RNA, Viral | 1 | 2020 | 2847 | 0.030 |
Why?
|
United States | 4 | 2023 | 67165 | 0.030 |
Why?
|
Spleen | 1 | 2017 | 2473 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2007 | 4969 | 0.030 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1572 | 0.030 |
Why?
|
Placebos | 1 | 2016 | 1733 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2016 | 1908 | 0.030 |
Why?
|
Drug Interactions | 1 | 2015 | 1456 | 0.030 |
Why?
|
Abdominal Fat | 1 | 2012 | 224 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1778 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2020 | 1969 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 10857 | 0.020 |
Why?
|
Hypertrophy | 1 | 2012 | 579 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 973 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 3075 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3436 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3455 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1693 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2018 | 3179 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2021 | 5141 | 0.020 |
Why?
|
Atrophy | 1 | 2012 | 1509 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2428 | 0.020 |
Why?
|
Body Constitution | 1 | 2007 | 275 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4015 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2007 | 278 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2340 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 15274 | 0.020 |
Why?
|
Phosphorus | 1 | 2007 | 357 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2006 | 194 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5833 | 0.020 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 292 | 0.020 |
Why?
|
Menstruation | 1 | 2005 | 288 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2021 | 11718 | 0.020 |
Why?
|
Homeostasis | 1 | 2014 | 3334 | 0.020 |
Why?
|
Thorax | 1 | 2005 | 512 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1346 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 8072 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2007 | 790 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1047 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9774 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5267 | 0.010 |
Why?
|
Ovary | 1 | 2005 | 997 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8024 | 0.010 |
Why?
|
Anthropometry | 1 | 2005 | 1367 | 0.010 |
Why?
|
Transcription Factors | 1 | 2019 | 12005 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6766 | 0.010 |
Why?
|
Energy Intake | 1 | 2007 | 2136 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9556 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7487 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13298 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 12447 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 6989 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 58184 | 0.010 |
Why?
|
Mice | 1 | 2021 | 80876 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 28919 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7644 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 34151 | 0.010 |
Why?
|
Bone Density | 1 | 2005 | 3395 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 13536 | 0.010 |
Why?
|
Neoplasms | 1 | 2017 | 20172 | 0.010 |
Why?
|
Animals | 1 | 2021 | 170486 | 0.010 |
Why?
|